Sibel Health

Develops advanced medical monitoring sensors

Evanston, Illinois, United States

About Sibel Health

Sibel Health focuses on enhancing patient outcomes through advanced medical monitoring solutions. Its main product, the ADAM sensor, captures detailed physiological data using features like a three-axis accelerometer, gyroscope, temperature sensing, and Bluetooth Low Energy (BLE) connectivity. The sensor is designed for single-use and adheres gently to the skin for continuous monitoring, making it suitable for a wide range of patients from neonates to adults. Sibel Health differentiates itself by providing FDA-cleared devices that meet strict regulatory standards, ensuring trust among healthcare providers. The company's goal is to deliver better health data for all, enabling proactive monitoring and intervention to improve patient care and outcomes.

Evanston, IllinoisHeadquarters
2018Year Founded
$51.3MTotal Funding
GRANTCompany Stage
Data & Analytics, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Professional Development Budget
Unlimited Paid Time Off
Company Social Events

Risks

Increased competition in wearable health monitoring could threaten Sibel Health's market share.
Rapid AI advancements may require continuous software updates to stay competitive.
Supply chain vulnerabilities could disrupt production and delivery schedules.

Differentiation

Sibel Health's ADAM sensor offers advanced features like a three-axis accelerometer and gyroscope.
The company provides FDA-cleared devices, ensuring high regulatory standards and trust.
Sibel Health's sensors are designed for single-use, enhancing hygiene and reducing infection risks.

Upsides

Sibel Health received a $17.5 million grant from the Gates Foundation for maternal monitoring.
The company closed a $33 million Series B financing round for platform development.
Sibel Health's collaboration with Medidata enhances data collection for clinical trials.

Funding

Total raised$51.32 M
Latest valuation$165.00 M
StageGRANT
$33
$165.00 M
SEED
2/28/2021
$2
$11.03 M